IndraLab

Statements

Bufexamac inhibits IFNB1. 2 / 2

| 2

reach

"While both Bufexamac and TSA treatment blocked IFN-beta promoter induction by SenV in a dose dependent manner, treatment of cells with VPA did not decrease IFN-beta promoter induction as compared to nontreated cells (XREF_FIG A)."

27372014

➶

reach

"TSA also blocked IFN-beta promoter induction by the constitutively active N-RIG construct but importantly, Bufexamac treatment did not block IFN-beta promoter induction by N-RIG."

27372014

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

Bufexamac inhibits IFNB1. 2 / 2

INDRA sources:

Databases

Reading